Does Curcumin or Pindolol Potentiate Fluoxetine's Antidepressant Effect by a Pharmacokinetic or Pharmacodynamic Interaction?

@article{Murad2014DoesCO,
  title={Does Curcumin or Pindolol Potentiate Fluoxetine's Antidepressant Effect by a Pharmacokinetic or Pharmacodynamic Interaction?},
  author={Hussam A. S. Murad and Mansour I Suliaman and Heba M.I. Abdallah and May A. Abdulsattar},
  journal={Indian Journal of Pharmaceutical Sciences},
  year={2014},
  volume={76},
  pages={203 - 210}
}
This study was designed to study potentiation of fluoxetine's antidepressant effect by curcumin or pindolol. Twenty eight groups of mice (n=8) were used in three sets of experiments. In the first set, 9 groups were subjected to the forced swimming test after being treated intraperitoneally with three vehicles, fluoxetine (5 and 20 mg/kg), curcumin (20 mg/kg), pindolol (32 mg/kg), curcumin+fluoxetine (5 mg/kg) and pindolol+fluoxetine (5 mg/kg). One hour after the test, serum and brain fluoxetine… Expand
5 Citations
Comparative Study on the Activity of Agomelatine and/or Curcumin against Development of Depression in Rats
Background: The depressive disorders in both developed and developing countries constitute a large proportion in the global burden of disease. Curcumin is the frequently used herb Turmeric, which wasExpand
Pharmacokinetic interactions of curcuminoids with conventional drugs: A review.
TLDR
Curcumin can induce pharmacokinetic alterations such as changes in Cmax and AUC when concomitantly used with pharmacological agents like cardiovascular drugs, antidepressants, anticoagulants, antibiotics, chemotherapeutic agents, and antihistamines. Expand
Thymoquinone harbors protection against Concanavalin A-induced behavior deficit in BALB/c mice model.
TLDR
Positive results of current study propose thymoquinone as an affordable, natural antidepressant drug candidate with better safety profile than currently available antidepressant regimes, paving the way for effective drug development against treatment-resistant depression. Expand
Natural Polyphenols and Terpenoids for Depression Treatment: Current Status
TLDR
Evidence on the antidepressant effects elicited by natural compounds belonging to polyphenol and terpenoid classes and their mechanisms of action is reviewed. Expand
Curcumin for neuropsychiatric disorders: a review of in vitro, animal and human studies
TLDR
In this systematic review, in vitro, animal, and human studies investigating the potential of curcumin as a treatment for neuropsychiatric disorders such as major depressive disorder, post-traumatic stress disorder (PTSD), obsessive-compulsive disorder (OCD), bipolar disorder, psychotic disorders, and autism are reviewed, and directions for future research are proposed. Expand

References

SHOWING 1-10 OF 41 REFERENCES
Evaluation of antidepressant like activity of curcumin and its combination with fluoxetine and imipramine: an acute and chronic study.
TLDR
Curcumin increased both the swimming and climbing behavior in FST, thus its antidepressant like activity could be due to an increase in serotonin, norepinephrine and dopamine levels in the brain. Expand
Acute treatments with GMP produce antidepressant‐like effects in mice
TLDR
The results suggest that the antidepressant–like effects produced by the administration of GMP, like MK-801, may be due to an indirect serotonin activation resulting from blockade of NMDA receptors. Expand
The antidepressant effects of curcumin in the forced swimming test involve 5-HT1 and 5-HT2 receptors.
TLDR
Results indicate that the antidepressant-like effect of curcumin in the forced swimming test is related to serotonergic system and may be mediated by, at least in part, an interaction with 5- HT(1A/1B) and 5-HT(2C) receptors. Expand
Effects of chronic fluoxetine treatment in the presence and absence of (±)pindolol: a microdialysis study
TLDR
It would appear that although (±)pindolol alone has sufficient intrinsic activity to produce a desensitization of the 5‐HT1A receptor, when given in combination with fluoxetine it is able to prevent the desensItization induced by not only fluoxettine but also itself. Expand
Synergistic effect of imipramine and amantadine in the forced swimming test in rats. Behavioral and pharmacokinetic studies.
TLDR
The above result suggests that the dopamine D(2/3) and alpha(1)-adrenergic receptors may contribute to the mechanism of synergistic action of IMI and AMA in the forced swimming test in rats. Expand
Psychopharmacological profile of the selective serotonin reuptake inhibitor, paroxetine: implication of noradrenergic and serotonergic mechanisms
TLDR
The results of the present study indicated that paroxetine displayed both noradrenergic- like and serotonergic-like activity in the pre-clinical psychopharmacological tests employed. Expand
Enhancement of the anti-immobility action of antidepressants by a selective 5-HT7 receptor antagonist in the forced swimming test in mice.
TLDR
The obtained results indicate that blockade of 5-HT7 receptors may facilitate the anti-immobility effect of antidepressants in mice. Expand
Serotonergic agents modulate antidepressant-like effect of the neurosteroid 3alpha-hydroxy-5alpha-pregnan-20-one in mice.
TLDR
It is demonstrated for the first time that serotonergic agents potentiate the antidepressant-like action of 3alpha, 5alpha THP, by enhancing the GABAergic tone as a likely consequence of increased brain content of this neurosteroid. Expand
Is the beneficial antidepressant effect of coadministration of pindolol really due to somatodendritic autoreceptor antagonism?
BACKGROUND We investigated the combination of selective serotonin reuptake inhibitors (SSRIs) with the beta-adrenoceptor/serotonin 1A (5-HT(1A)) antagonist pindolol, based on the concept thatExpand
Synergistic effect of uncompetitive NMDA receptor antagonists and antidepressant drugs in the forced swimming test in rats
TLDR
The present results suggest that the combination of traditional antidepressant drugs and NMDA receptor antagonists may produce enhanced antidepressive effects, and this is of particular relevance for antidepressant-resistant patients. Expand
...
1
2
3
4
5
...